NCT06648057 Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
| NCT ID | NCT06648057 |
| Status | Recruiting |
| Phase | — |
| Sponsor | CHA University |
| Condition | Biliary Tract Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-09-23 |
| Primary Completion | 2026-09-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-09-23 with a primary completion date of 2026-09-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to evaluate the clinical efficacy and safety of lenvatinib plus pembrolizumab combination therapy in patients with advanced biliary tract cancer (BTC). This study aims to identify potential biomarkers that may predict treatment response by analyzing genetic data from blood and tissue samples. The study will focus on real-world clinical outcomes and the exploratory discovery of biomarkers associated with the efficacy of this treatment regimen.
Eligibility Criteria
Inclusion Criteria: * Patients with histologically or cytologically confirmed advanced biliary tract cancer. * Patients scheduled to receive Lenvatinib + Pembrolizumab for the treatment of advanced biliary tract cancer. * ECOG performance status of 0-2. * Patients aged 20 years or older at the time of treatment initiation. * Patients who understand and consent to participate in this study, and agree to provide samples obtained during the examination process. Exclusion Criteria: * Patients who do not consent to participate in the study or withdraw their consent.
Contact & Investigator
Hong Jae Chon, MD. PhD
PRINCIPAL INVESTIGATOR
CHA University
Frequently Asked Questions
Who can join the NCT06648057 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Biliary Tract Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06648057 currently recruiting?
Yes, NCT06648057 is actively recruiting participants. Contact the research team at minidoctor@cha.ac.kr for enrollment information.
Where is the NCT06648057 trial being conducted?
This trial is being conducted at Seongnam-si, South Korea.
Who is sponsoring the NCT06648057 clinical trial?
NCT06648057 is sponsored by CHA University. The principal investigator is Hong Jae Chon, MD. PhD at CHA University. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.